Marine Compounds as Anti-Alzheimer's Agent

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 3120

Special Issue Editors


E-Mail Website
Guest Editor
Department of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea
Interests: protein structure and dynamics; protein conformational disorders; drug design; protein–protein interaction; neurodegenerative diseases; molecular modeling
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Biochemistry and Molecular Biology, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh
Interests: bioactive natural products with neuroprotective potentials; molecular neuropharmacology; system pharmacology; functional foods; computational biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Alzheimer’s disease is the most common progressive neurodegenerative disorder and the major cause of dementia. The main pathological hallmarks of AD include extracellular deposition of amyloid plaque, intraneuronal aggregation of neurofibrillary tangles, and brain atrophy. The therapeutic strategy of AD requires a multitargeted approach because of its multifaceted pathobiology. Oxidative stress, neuroinflammation, and an impaired protein clearance system constitute primary contributing factors in the pathogenesis of AD and can therefore be potential targets for the development of anti-AD agents. Although synthetic and semisynthetic drugs are the primary source of therapeutics against AD, their adverse side effects have led researchers to search for therapeutic leads from natural compounds. Diverse marine organisms are offering a wonderful source of natural compounds. Marine natural products are shown to be effective in attenuating AD pathobiological processes. Many of these compounds modulate various molecular targets of brain-specific biochemical and signaling pathways, suggesting their therapeutic significance in the management of neurodegenerative disorders, including AD. Natural product researchers and drug designers have been focusing their attention on the discovery and development of novel therapeutic leads from marine natural products or their skeleton.

This Special Issue will cover the identification and characterization of novel compounds from marine organisms, the bioactivity of already known molecules, structure-activity relationship, strategies for brain delivery, and the mechanism of neuroprotection against various toxic insults representing in vitro and in vivo models of AD. Both original research and review papers are welcome.

Prof. Dr. II Soo Moon
Prof. Dr. Md Abdul Hannan 
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine natural products
  • identification and characterization of marine compounds and their structure-activity relationships
  • mechanistic insights through experimental and bioinformatics approaches
  • antioxidant, anti-inflammatory, anti-cholinesterase, and anti-amyloid properties
  • nano-guided drug delivery
  • neuroprotection
  • Alzheimer’s disease and associated complications, such as diabetes-induced cognitive deficits

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:
12 pages, 2073 KiB  
Article
Astaxanthin: A Marine Drug That Ameliorates Cerebrovascular-Damage-Associated Alzheimer’s Disease in a Zebrafish Model via the Inhibition of Matrix Metalloprotease-13
by Nallupillai Paramakrishnan, Khian Giap Lim, Yamunna Paramaswaran, Nemat Ali, Mohammad Waseem, Gamal A. Shazly, Yousef A. Bin Jardan and Arunachalam Muthuraman
Mar. Drugs 2023, 21(8), 433; https://doi.org/10.3390/md21080433 - 31 Jul 2023
Cited by 3 | Viewed by 2458
Abstract
Alzheimer’s disease (AD) is a major type of dementia disorder. Common cognitive changes occur as a result of cerebrovascular damage (CVD) via the disruption of matrix metalloproteinase-13 (MMP-13). In diabetic cases, the progress of vascular dementia is faster and the AD rate is [...] Read more.
Alzheimer’s disease (AD) is a major type of dementia disorder. Common cognitive changes occur as a result of cerebrovascular damage (CVD) via the disruption of matrix metalloproteinase-13 (MMP-13). In diabetic cases, the progress of vascular dementia is faster and the AD rate is higher. Patients with type 2 diabetes are known to have a higher risk of the factor for AD progression. Hence, this study is designed to investigate the role of astaxanthin (AST) in CVD-associated AD in zebrafish via the inhibition of MMP-13 activity. CVD was developed through the intraperitoneal and intracerebral injection of streptozotocin (STZ). The AST (10 and 20 mg/L), donepezil (1 mg/L), and MMP-13 inhibitor (i.e., CL-82198; 10 μM) were exposed for 21 consecutive days in CVD animals. The cognitive changes in zebrafish were evaluated through light and dark chamber tests, a color recognition test, and a T-maze test. The biomarkers of AD pathology were assessed via the estimation of the cerebral extravasation of Evans blue, tissue nitrite, amyloid beta-peptide aggregation, MMP-13 activity, and acetylcholinesterase activity. The results revealed that exposure to AST leads to ameliorative behavioral and biochemical changes. Hence, AST can be used for the management of AD due to its multi-targeted actions, including MMP-13 inhibition. Full article
(This article belongs to the Special Issue Marine Compounds as Anti-Alzheimer's Agent)
Show Figures

Graphical abstract

Back to TopTop